Sintx Technologies, Inc. (SINT) Company Overview

What does SINTX Technologies do?

SINTX Technologies, Inc. is a Salt Lake City advanced-ceramics company traded on the Nasdaq Capital Market under the ticker SINT. Its central asset is expertise in silicon nitride, a high-performance ceramic used in medical implants and other demanding applications. The company develops materials, components, coatings, composites, and finished devices, while also providing technical and contract manufacturing. The most useful way to understand SINTX is not as a conventional orthopedic-device company, but as a small biomaterials platform trying to convert decades of silicon-nitride research into several commercial channels.

Why does the material platform matter?

The FY2025 Form 10-K describes one reportable operating segment, even though the commercial proposition spans several end markets. Medical applications include spinal fusion, foot-and-ankle reconstruction, coatings, and silicon-nitride/PEEK composites. Non-medical opportunities include aerospace, electrical, industrial, antipathogenic, and agribiotech uses. The company’s public website presents the same platform logic: silicon nitride can be sold as a finished component, powder, coating, composite ingredient, or manufacturing capability rather than only as one branded implant.

How does SINTX make money, and which revenue stream matters most?

SINTX currently earns revenue in two accounting categories: product revenue and grant-and-contract revenue. Product revenue comes from manufactured components, coatings, materials, toll-processing services, and medical or aerospace-related products. Grant-and-contract revenue comes primarily from government-supported development programs. Revenue is generally recognized when control transfers to the customer, typically upon shipment. This is a project and product model, not a subscription model, so order timing, customer qualification, manufacturing yields, and delivery schedules can create uneven quarterly results.

What did the FY2025 revenue mix look like?

FY2025 total revenue was $1.018 million, down 65% from FY2024 as SINTX exited non-core, low-margin activity and sold the TA&T subsidiary. Product revenue declined 41% to $0.729 million and grant-and-contract revenue declined 82% to $0.289 million. That contraction was partly intentional, but it left the company with a very small revenue base relative to its operating cost structure.

What did SINTX’s latest quarter show?

The latest filed financial period is the quarter ended March 31, 2026. The Q1 2026 Form 10-Q showed modest top-line growth but a much larger operating loss and a rapid decline in liquidity. Revenue was $0.380 million, up 3% year over year. Excluding the prior-year contribution of the divested TA&T operation, management calculated that continuing revenue increased 46%. Product revenue was $0.300 million and grant-and-contract revenue was $0.080 million.

Why did the margin improve while the loss widened?

Strategic history: from spine implants to a broader biomaterials platform

SINTX has repeatedly changed the commercial structure around its material science: direct spine devices, licensing and OEM work, broader ceramics, and now a refocused biomaterials platform supported by contract manufacturing.

1. 1996
   Formation around medical-grade silicon nitride created the knowledge and patents that still anchor SINTX.
2. 2008
   Spinal implants entered human use, establishing a clinical history for the material.
3. 2014
   Amedica completed its Nasdaq listing, gaining equity access and public-market compliance obligations.
4. 2018
   SINTX sold its spine implant business to CTL Medical and transferred or licensed related patents, emphasizing a biomaterial-supplier role.
5. 2021–2024
   Expansion into armor failed to reach sustainable operation; the board approved a shutdown plan in August 2024.
6. 2025
   SINTX divested TA&T, acquired Sinaptic Surgical, refreshed the board, raised approximately $10M during the year, and obtained FDA 510(k) clearance for the SINAPTIC foot-and-ankle wedge system.
7. March 2026
   The first SINAPTIC procedure on March 13 moved the platform from clearance to clinical use.
8. June 2026
   SINTX raised equity and announced more than $3.2M of orders expected to ship from 2H 2026 into 2027.

The company’s March 2026 corporate update framed this sequence as a transition from restructuring to commercial execution. Those are milestones, not yet proof of durable revenue or cash generation.

What gives SINTX a competitive advantage?

SINTX’s moat is technical, combining silicon-nitride formulation, patents, research, regulatory history, and in-house manufacturing. The FY2025 filing cites more than 130 peer-reviewed publications and presentations and describes a manufacturing facility that controls the process from raw material through finished components. It also states that SINTX is the only company to have developed and manufactured ceramic products used in FDA-cleared spinal-fusion devices and FDA-cleared osteotomy wedges in the United States.

Which resources could be durable?

Material properties provide the scientific basis for differentiation. The filing describes silicon nitride as osteointegrative, resistant to bacterial adhesion, compatible with X-ray, CT, and MRI imaging, hard, fracture-resistant, non-corrosive, and suitable for coatings or composites. In company-cited preclinical testing, separation force from bone was approximately three times PEEK and nearly twice titanium in the absence of bacteria; live bacterial counts were reported as 8 to 30 times lower than on PEEK and up to 8 times lower than on titanium. Broader adoption still depends on product outcomes, surgeon familiarity, reimbursement, and labeling.

The official SINTX website shows why management increasingly uses platform language: powders, coatings, composites, implants, and additive-manufacturing feedstocks can all originate from the same core expertise. Each application also adds separate qualification, regulatory, and channel requirements.

Who are SINTX’s main competitors?

Competition comes from biomaterials and device companies. Alternatives include PEEK, BIOLOX delta, allograft, metals, coatings, and additive-manufactured materials. Device rivals have established surgeons, broad portfolios, large sales forces, and greater resources. The filing names Medtronic, DePuy Synthes, Stryker, Zimmer Biomet, CeramTec, Kyocera, CoorsTek, BactiGuard, and Microban.

Where does SINTX sit strategically?

How financially strong is SINTX?

SINTX is not financially self-sustaining. FY2025 revenue of $1.018 million produced $0.461 million of gross profit against $11.182 million of operating expenses and a $10.364 million net loss. Financing activities supplied $8.200 million, underscoring dependence on external capital.

What does the balance sheet say?

Management concluded that substantial doubt remained about the company’s ability to continue as a going concern for at least 12 months from issuance of the Q1 2026 statements. The company subsequently announced a June 2026 financing consisting of a $4.5 million private placement of 1,882,845 shares and accompanying Class A and Class B warrants, plus a previously completed $0.5 million ATM sale. The financing announcement said proceeds were intended for working capital, commercialization, business development, and strategic opportunities.

The financing improves liquidity but adds potential warrant dilution; more capital may be needed unless revenue converts quickly. The May 2026 Nasdaq notice reported that stockholders’ equity was below the $2.5 million continued-listing threshold and that the company did not then satisfy the alternative market-value or net-income standards.

Who owns SINTX stock, and how is the company governed?

SINTX has one vote per common share and no dual-class founder control, but frequent stock and warrant issuance changes ownership rapidly. The latest full beneficial-ownership table available in the 2025 proxy statement was measured as of July 1, 2025, before several later equity transactions. It should be read as a governance snapshot, not a current cap table.

How does leadership affect the strategy?

Eric Olson remains chairman and chief executive officer. Ryan Elmore became president effective March 16, 2026, with a mandate to execute commercialization, channel development, OEM relationships, and strategic partnerships. His Invibio background is relevant because PEEK is both a competitor and part of the SiNERGY composite platform. The current management page also shows a leadership team weighted toward medical devices, commercialization, legal execution, and financing.

Commercialization opportunities and risks that define the outlook

Where could growth come from?

The clearest near-term opportunity is contract manufacturing. On June 22, 2026, SINTX announced purchase orders above $3.2 million, with shipments expected from 2H 2026 into 2027. The value is large relative to FY2025 revenue of $1.018 million, but orders remain modifiable or cancellable. The purchase-order announcement therefore improves visibility but does not equal guaranteed backlog conversion.

SINAPTIC is the clearest proprietary-device catalyst: FDA clearance came in October 2025 and first human use on March 13, 2026. The first-in-human announcement established initial clinical use, but market penetration requires trained surgeons, hospital access, inventory, distribution economics, reimbursement support, and consistent outcomes. Longer-term opportunities include SiNERGY composites, coatings, fibers, additive-manufacturing formats, and agribiotech.

What could weaken the story?

What should a DCF analyst monitor next?

A conventional DCF is difficult because cash flow is negative, revenue is small, and equity or warrants can change the capital structure. A milestone-based model should test whether manufacturing and proprietary products can cover fixed commercial, quality, and public-company costs.

Which operating KPIs matter most?

The downside case should include delayed orders, slower adoption, more financing, and dilution. The upside case should require repeat programs, expanding gross profit, partnership economics, and a path toward cost coverage. Probability weighting is more defensible than one smooth growth curve.

What is the key takeaway from SINTX Technologies analysis?

SINTX is technically differentiated but financially fragile. Silicon-nitride expertise, FDA-cleared products, patents, research, and manufacturing form its strategic asset. The March 2026 first human use of the SINAPTIC wedge and the June 2026 purchase orders provide stronger commercial signals than the company had at the end of FY2025.

For students, SINTX is a useful case study in the difference between technological advantage and economic advantage. For researchers, it illustrates how patents, regulatory clearances, manufacturing quality, and clinical evidence interact. For valuation work, the next several reporting periods should be treated as a test of commercialization: whether more than $3.2 million of announced orders, the SINAPTIC launch, and partner-led materials programs can transform a high-potential platform into a business capable of funding itself.